U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O4S.Zn.H2O
Molecular Weight 179.487
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC SULFATE MONOHYDRATE

SMILES

O.[Zn++].[O-]S([O-])(=O)=O

InChI

InChIKey=RNZCSKGULNFAMC-UHFFFAOYSA-L
InChI=1S/H2O4S.H2O.Zn/c1-5(2,3)4;;/h(H2,1,2,3,4);1H2;/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula HO4S
Molecular Weight 97.071
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Originator

Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: ultraviolet B-induced damage
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.
1997 May 16
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.
2004 Jul 30
High-throughput computational and experimental techniques in structural genomics.
2004 Oct
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
Erythrocyte zinc content in critically ill patients.
2005
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
2005 Aug
Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise.
2005 May
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.
2005 Nov-Dec
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.
2005 Sep 1
Characterization and inhibition of SARS-coronavirus main protease.
2006
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
2007 May
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011 Nov 30
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.
2012 Mar
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015 Apr 2
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016 Oct
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Sample Use Guides

Rats: The dose of zinc hydroxide administered to each rat was 85 mg/kg and represented 40% of the recommended daily allowance of a male adult human. This dose was administered in water solution at a final volume of 1 mL per rat.
Route of Administration: Oral
In Vitro Use Guide
Zinc hydroxide (1 mM) stimulates superoxide production by rat alveolar macrophages, as determined by CLA-dependent chemiluminescence.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:44:23 UTC 2023
Edited
by admin
on Wed Jul 05 23:44:23 UTC 2023
Record UNII
PTX099XSF1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC SULFATE MONOHYDRATE
EP   MI   VANDF   WHO-DD   WHO-IP  
Systematic Name English
ZINCI SULFAS MONOHYDRATE [WHO-IP LATIN]
Common Name English
ZINC SULFATE MONOHYDRATE [EP MONOGRAPH]
Common Name English
ZINC SULFATE MONOHYDRATE [MI]
Common Name English
ZINC SULPHATE (1:1) MONOHYDRATE
Common Name English
ZINC SULFATE (1:1) MONOHYDRATE
Common Name English
SULFURIC ACID, ZINC SALT (1:1), MONOHYDRATE
Common Name English
ZINC SULFATE (MONOHYDRATE)
Systematic Name English
ZINC SULPHATE MONOHYDRATE
Systematic Name English
ZINC SULFATE MONOHYDRATE [WHO-IP]
Common Name English
ZINC SULFATE MONOHYDRATE [USP MONOGRAPH]
Common Name English
ZINC SULFATE MONOHYDRATE [VANDF]
Common Name English
ZINC SULPHATE (MONOHYDRATE)
Systematic Name English
Zinc sulfate monohydrate [WHO-DD]
Common Name English
ZINC SULFATE [WHO-IP]
Common Name English
Classification Tree Code System Code
EPA PESTICIDE CODE 527200
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
Code System Code Type Description
EVMPD
SUB22913
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY
DAILYMED
PTX099XSF1
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY
DRUG BANK
DBSALT001304
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY
NCI_THESAURUS
C45678
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
CONCEPT Industrial Aid
PUBCHEM
62639
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ZINC SULFATE MONOHYDRATE
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY Description: A white or almost white, crystalline powder, or colourless, transparent crystals. Solubility: Very soluble in water, practically insoluble in ethanol (~750 g/l) TS. Category: Adjunct to oral rehydration salts in( prevention and) treatment of dehydration due to diarrhoea; astringent. Storage: Zinc sulfate should be kept in a well-closed, non-metallic container. Labelling: The designation on the container should state whether the substance is in the monohydrate or heptahydrate form and, where appropriate, that it is suitable for use in the manufacture of parenteral dosage forms. Definition: Zinc sulfate monohydrate contains not less than 99.0% and not more than 101.0% of ZnSO4,H2O. Zinc sulfate heptahydrate contains not less than 99.0% and not more than 104.0% of ZnSO4,7H2O.
RXCUI
1309410
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID2035019
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY
CAS
7446-19-7
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY
SMS_ID
100000087994
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY
NCI_THESAURUS
C75660
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY
RS_ITEM_NUM
1724769
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY
FDA UNII
PTX099XSF1
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY
MERCK INDEX
M11629
Created by admin on Wed Jul 05 23:44:23 UTC 2023 , Edited by admin on Wed Jul 05 23:44:23 UTC 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY